These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1323 related articles for article (PubMed ID: 27324719)

  • 1. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand.
    Azariah S; Saxton P; Franklin R; Forster R; Werder S; Jenkins R
    BMJ Open; 2019 Jun; 9(6):e026363. PubMed ID: 31248921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
    Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
    Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.
    Jin X; Wang H; Li H; Chu Z; Zhang J; Hu Q; Lv W; Huang X; Chen Y; Wang H; He X; Zhang L; Hu Z; Bao R; Li S; Ding H; Geng W; Jiang Y; Shang H; Xu J;
    BMC Public Health; 2020 Jul; 20(1):1160. PubMed ID: 32709230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
    McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
    JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.
    Vaccher SJ; Grulich AE; Haire BG; Conway DP; Poynten IM; Ooi C; Foster R; Templeton DJ; Zablotska IB;
    PLoS One; 2017; 12(9):e0185398. PubMed ID: 28950022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.
    O'Halloran C; Rice B; White E; Desai M; Dunn DT; McCormack S; Sullivan AK; White D; McOwan A; Gafos M
    Int J Drug Policy; 2019 Dec; 74():246-254. PubMed ID: 31739177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
    Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
    BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project.
    Vaccher SJ; Marzinke MA; Templeton DJ; Haire BG; Ryder N; McNulty A; Foster R; Grulich AE; Zablotska IB; ;
    AIDS Behav; 2019 May; 23(5):1287-1296. PubMed ID: 30523489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.